Clinical trials: IPF
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Healthy Participants
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
- Trial name
- NCT05684289
- Testing
- BMS-986278, Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018_055 in healthy…
- Trial name
- NCT05154240
- Testing
- INS018_055
- Where
- New Zealand
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- InSilico Medicine Hong Kong Limited
Chronic Obstructive Pulmonary Disease, Asthma
Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects
The first-in-man study are designed as below to assess safety, tolerability, and preliminary pharmacokinetics of ZL-2102. Double-blind randomized, placebo-controlled ascending single oral doses (Part 1, ZL-2102-SAD); Open-label…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02397005
- Testing
- ZL-2102
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Zai Lab Pty. Ltd.
Idiopathic Pulmonary Fibrosis, Lung; Disease, Interstitial, With Fibrosis
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
This is a phase 1, randomized, First in Human (FIH), double-blinded, placebo-controlled study to assess the safety, tolerability, and PK of RSN0402 in healthy volunteers.
- Trial name
- NCT06482190
- Testing
- RSN0402 Part 1, RSN0402 Part 2
- Where
- 3 sites in Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shenzhen Resproly Biopharmaceutical Co., Ltd
COPD Asthma, Pulmonary Fibrosis
Accuracy of Spircare Device as Compared to the Conventional Plethysmograph
The purpose of this study is to assess the accuracy of FRC and airway resistance calculate values of Spircare device as compared to the conventional body plethysmograph in healthy adults and patients with obstructive and…
- Trial name
- NCT03056066
- Testing
- Plethysmograph
- Where
- Israel
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Spircare Ltd.
Pulmonary Fibrosis
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
- Trial name
- NCT07229716
- Testing
- HRS-9813 Capsule, Nintedanib Soft Capsules, Pirfenidone Tablets
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
GSK3008348 is an investigational drug, being developed by GlaxoSmithKline Research and Development Limited (the Sponsor, a pharmaceutical company based in the UK) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT02612051
- Testing
- GSK3008348 Nebuliser solution, GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis (IPF)
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 1, 4-part, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1058 inhaled solution.
- Trial name
- NCT04589260
- Testing
- TD-1058
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Safety Issues, Tolerance
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
This is a FIH, double-blind, placebo-controlled, within-group randomised, trial designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending oral doses of compound 106 (C106) in…
- Conditions
- Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Trial name
- NCT05427253
- Testing
- C106 solution
- Where
- Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vicore Pharma AB
Healthy Volunteers, Idiopathic Pulmonary Fibrosis
A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis
The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.
- Trial name
- NCT03949530
- Testing
- IDL-2965 Oral Capsule
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Indalo Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis (IPF)
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
This is a Phase I stage to investigate the safety and tolerability of MG-S-2525 in healthy volunteers. The proposed trial consists of 3 study parts to be conducted at Tri-Service General Hospital and includes Single Ascending…
- Trial name
- NCT03650075
- Testing
- MG-S-2525
- Where
- Taiwan
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Metagone Biotech Inc.
Idiopathic Pulmonary Fibrosis(IPF), Solid Tumor
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
The Primary objectives of this study are to evaluate the safety and tolerability of ZSP1603 and the Secondary objective is to estimate the pharmacokinetic (PK) parameters after orally administered once daily of ZSP1603.
- Trial name
- NCT03619616
- Testing
- ZSP1603 7.5 mg, ZSP1603 12.5 mg, ZSP1603 25 mg
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Drug Interactions
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
- Trial name
- NCT06717100
- Testing
- Nintedanib 150 MG [Ofev]
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PureTech
IPF
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants
This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of RC010 in healthy adult volunteers.
- Trial name
- NCT07528703
- Testing
- RC010 Inhalation Powder
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Nanjing Reju Therapeutics Co., Ltd
Idiopathic Pulmonary Fibrosis
The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects
- Trial name
- NCT03092102
- Testing
- HEC585
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.
- Trial name
- NCT07407543
- Testing
- SRN001, 0.9% sodium chloride (normal saline)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- siRNAgen Therapeutics Inc.
Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
The purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel LPA1 positron emission tomography (PET) ligand 18F-BMS-986327 in healthy participants and participants with…
- Trial name
- NCT04069143
- Testing
- 18F-BMS-986327
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed Conditions
A Randomized, Open-Label, Single-Dose, Double-period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets by Oral Administration in Healthy Chinese Subjects Under Fasting and Fed…
- Trial name
- NCT06569381
- Testing
- Pirfenidone Modified-Release Tablets
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Idiopathic Pulmonary Fibrosis
Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed Conditions
A Randomized, Open-Label, Two-Period, Double-Crossover Comparative Study on the Pharmacokinetics of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Chinese Subjects under Fed Conditions Primary objective…
- Trial name
- NCT06589921
- Testing
- Pirfenidone Modified-Release Tablets, Pirfenidone Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.